[Guidelines for the diagnosis and treatment of carbapenem-resistant pseudomonas aeruginosa infection(2026 edition)].

(CRPA) is an important pathogen of hospital acquired infections, especially in patients with chronic lung disease, long-term hospitalization, or those who have received broad-spectrum antibiotic treatment. CRPA often manifests as multidrug resistance, which can lead to difficult treatment and poor prognosis. In order to standardize the clinical management of CRPA infection in China and improve the standardization and accuracy of diagnosis and treatment, the Branch of Bacterial Infection and Drug Resistance Prevention of the Chinese Medical Association and the Infectious Diseases Specialty Committee of the Chinese Medical Education Association organized multidisciplinary experts to formulate norms and grading of recommendations, assessment, development, and evaluation methods in accordance with international guidelines. This guidance systematically focuses on and answers 10 key clinical questions, covering the core aspects of diagnosis and treatment, mainly including: the clinical application value of carbapenemases phenotype or genotype detection, the necessity and methods of combined drug susceptibility testing, adjustment of the treatment plan based on monitoring the minimum inhibitory concentration during the treatment process, the role of drug concentration monitoring in optimizing dosing regimens, comparison of the efficacy of polymyxin monotherapy and combination therapy, the treatment indications and strategies for chronic pulmonary CRPA infection, the clinical application of inhaled antibiotics and azithromycin, the role of intravenous combined nebulization inhalation therapy in acute pulmonary infections, recommendations for the treatment of central nervous system infections with intravenous combined intrathecal/intraventricular administration, and combined treatment strategies for severe CRPA infections. This guideline aims to provide practical guidance for clinical physicians based on current evidence, emphasizing individualized comprehensive treatment based on precise detection and individual patient conditions, in order to improve the clinical outcomes of CRPA infected patients and promote the rational use of antibiotics.